Consumer Health Cancer / Immunology
Irish oncology care platform announces collaboration with NCCN
The Irish-founded oncology software company, ONCOassist, today announces a new agreement with The National Comprehensive Cancer Network® (NCCN®). T...
October 18, 2022 | News
Chinese NMPA Approves Pivotal Phase III Study of TLX591-CDx for Prostate Cancer Imaging
The IND application was submitted in partnership with Grand Pharmaceutical Group Limited (Grand Pharma), Telix's partner in the Greater China reg...
October 17, 2022 | News
Health Canada Approves Illuccix® for Prostate Cancer Imaging
Illuccix™ [kit for the preparation of gallium (68Ga) gozetotide injection], after radiolabeling with gallium (68Ga), is indicated for use with the po...
October 14, 2022 | News
First patient treated in Clarity's therapeutic prostate cancer trial
Clarity Pharmaceuticals recruits and treats its first patient in the therapeutic phase of its SAR-bisPSMA theranostic clinical trial SECuRE (NCT0...
October 10, 2022 | News
United Imaging Announces Clinical System Installations at Huntsman Cancer Institute at the University of Utah
United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, announced that The Center for Quantitative Cancer Imaging ...
September 16, 2022 | News
Merck announced that the IAP (inhibitor of apoptosis protein) inhibitor xevinapant (formerly known as Debio 1143) plus chemoradiotherapy (CRT) markedly improved long-term efficacy outcomes in patients
First randomized trial in decades to show significant improvement in overall survival in patients with LA SCCHN, reinforcing the transformative potential...
September 14, 2022 | News
Merck to Highlight Data at ESMO 2022 with Potential for Transformative Impact on Cancer Patients
Late-breaking data highlight 5-year survival results from Phase II study of the investigational IAP inhibitor xevinapant in the curative setting of unres...
September 08, 2022 | News
Breast Cancer AI Company FathomX Raises SGD$ 2.24 million in Pre-series A Funding
Through this funding, the company will be able to harness the full potential of its digital AI solution to read medical images including mammograms. The fu...
September 02, 2022 | News
Lunit AI Solution for Breast Cancer Detection Wins Commercial Approval in Taiwan
Lunit (KRX: 328130.KQ), a leading medical AI provider, today announced that it received commercial approval in Taiwan for Lunit INSIGHT MMG, the ...
August 26, 2022 | News
Menarini Group's Elacestrant Marketing Authorization Application Accepted for Review by the European Medicines Agency (EMA)
lacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from second-line...
August 21, 2022 | News
Sirnaomics Commence Treatment of Facial Squamous Cell Skin Cancer In Situ
Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi t...
August 19, 2022 | News
ZAODX World Conference on Early Detection of Cancer was successfully held in Guangzhou, China
In attendance were founders and representatives from over 100 leading companies and institutions involved in cancer screening and early detection from nume...
August 01, 2022 | News
AI-based Cancer Solution Pioneer Lunit Makes Market Debut
Lunit expects to raise approximately KRW 36.4 billion (US$ 28 million). Lunit intends to use the proceeds for R&D of its new AI products and ...
July 22, 2022 | News
New discovery in cancer progression paves way to combat cancer
The life span of a normal healthy cell is determined by telomeres, protective caps at the ends of chromosomes. Each time a cell divides, the telomeres beco...
July 21, 2022 | News
Most Read
- How Health Systems Are Reshaping Drug Adoption, Partner Models, and Market Access in 2026
- Top 25 Biotech Innovations Redefining Health And Planet In 2025
- The New AI Gold Rush: Western Pharma’s Billion-Dollar Bet on Chinese Biotech
- Top 25 Biotech & Biopharma Leaders in Sustainable Innovation, 2025
- China’s Biopharma Dealmaking Surges in H1 2025, Driven by Record Licensing and Oncology Focus
- Chikungunya in China: How a “Forgotten” Arbovirus Found the Perfect Storm
- How Innovation Gaps in Biopharma Raise New Safety Concerns
- Smart Implants and the Future of Musculoskeletal Injury Treatment
- How Ethical Gaps in Psychiatry Could Undermine Biopharma Progress
- The Evolving Landscape of Women’s Health Innovation in the Asia-Pacific
- Using NLP-Driven Decision Support in Emergency Health Assistance
- Taiwan Steps Into the Global Spotlight With a New Cancer Therapy
- The Role of Unique Device Identification (UDI) in Tracing Medical Device Safety
- The Importance of a Patient’s Mental Health During Clinical Trials
Bio Jobs
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Avantor’s New CEO Ligner Aims to Unlock Global Potential and Deliver Shareholder Value
- AstraZeneca Commits $50 Billion to U.S. Expansion by 2030 in Biggest-Ever Global Investment
- Thermo Fisher, SAMRC, and South Africa’s Department of Science and Innovation Launch CATIR to Nurture Next-Gen Scientists
- Cube Biotech Appoints Former Sartorius CEO Dr. Joachim Kreuzburg to Board of Directors
- FDA’s AI Transition Marks a Turning Point in Drug Review: Industry Faces Pressure to Adapt Amid 20% Workforce Cut
- WuXi XDC Completes Mechanical Build of Singapore Bioconjugate Manufacturing Hub
News
Editor Picks
